Pancreatic Cancer Research

ResearcherHarbin Medical UniversityActive in the last 2 years

Rui Kong

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6863-3125; OpenAlex author ID A5009575914, A5100684765. Sources: OpenAlex.

Their work

Papers
25 (first author 3, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
53
Papers, trials and grants by year

2011: 2 papers · 2012: 2 papers · 2013: none · 2014: 1 paper · 2015: none · 2016: 4 papers · 2017: 1 paper · 2018: 2 papers · 2019: 2 papers · 2020: 2 papers · 2021: 1 paper · 2022: 1 paper · 2023: 3 papers · 2024: none · 2025: none · 2026: 4 papers

Papers 25

  1. Corrigendum to "Prometastatic secretome trafficking via exosomes initiates pancreatic cancer pulmonary metastasis" [Cancer Lett. 481 (2020) 63-75]. Co-author DOI 10.1016/j.canlet.2025.218119↗
  2. Tumour-infiltrating adipocyte-derived 12,13-DiHOME subverts CD8+ T cell immunity in pancreatic ductal adenocarcinoma by promoting PPARγ-mediated ferritinophagy… Co-author DOI 10.1136/gutjnl-2025-337119↗
  3. Spatial Multiomics Analyses Reveal That Diabetes Promotes Pancreatic Cancer Progression by Stimulating Cholesterol-Induced Neutrophil Extracellular Trap Format… Co-author DOI 10.1158/0008-5472.can-25-2854↗
  4. Mechanism of Artemisia argyi in the Treatment of Pancreatic Ductal Adenocarcinoma Based on Network Pharmacology and Experimental Validation. Last author DOI 10.2174/0118715206439346260326193041↗
  5. DUSP2 recruits CSNK2A1 to suppress AKT1-mediated apoptosis resistance under hypoxic microenvironment in pancreatic cancer. First author DOI 10.1016/j.canlet.2023.216288↗
  6. circEIF3I facilitates the recruitment of SMAD3 to early endosomes to promote TGF-β signalling pathway-mediated activation of MMPs in pancreatic cancer. Co-author DOI 10.1186/s12943-023-01847-2↗
  7. Caprin-1 influences autophagy-induced tumor growth and immune modulation in pancreatic cancer. Co-author DOI 10.1186/s12967-023-04693-4↗
  8. Positive feedback regulation of lncRNA TPT1-AS1 and ITGB3 promotes cell growth and metastasis in pancreatic cancer. Co-author DOI 10.1111/cas.15388↗
  9. Invadopodia: A potential target for pancreatic cancer therapy. Last author DOI 10.1016/j.critrevonc.2021.103236↗
  10. Prometastatic secretome trafficking via exosomes initiates pancreatic cancer pulmonary metastasis. Co-author DOI 10.1016/j.canlet.2020.02.039↗
  11. Small Molecule Inhibitor C188-9 Synergistically Enhances the Demethylated Activity of Low-Dose 5-Aza-2'-Deoxycytidine Against Pancreatic Cancer. Co-author DOI 10.3389/fonc.2020.00612↗
  12. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway. Co-author DOI 10.1186/s13045-019-0837-z↗
  13. Overexpression of KLF5 is associated with poor survival and G1/S progression in pancreatic cancer. First author DOI 10.18632/aging.102096↗
  14. Crucial microRNAs and genes in metformin's anti-pancreatic cancer effect explored by microRNA-mRNA integrated analysis. Co-author DOI 10.1007/s10637-017-0508-2↗
  15. MiR-361-3p regulates ERK1/2-induced EMT via DUSP2 mRNA degradation in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41419-018-0839-8↗
  16. Silencing IGFBP-2 decreases pancreatic cancer metastasis and enhances chemotherapeutic sensitivity. Co-author DOI 10.18632/oncotarget.18669↗
  17. Hyperoside induces apoptosis and inhibits growth in pancreatic cancer via Bcl-2 family and NF-κB signaling pathway both in vitro and in vivo. Co-author DOI 10.1007/s13277-015-4552-2↗
  18. Long Noncoding RNA MALAT1 Promotes Aggressive Pancreatic Cancer Proliferation and Metastasis via the Stimulation of Autophagy. Co-author DOI 10.1158/1535-7163.mct-16-0008↗
  19. Dihydroartemisinin suppresses pancreatic cancer cells via a microRNA-mRNA regulatory network. Co-author DOI 10.18632/oncotarget.11517↗
  20. Plasma and tumor levels of Linc-pint are diagnostic and prognostic biomarkers for pancreatic cancer. Co-author DOI 10.18632/oncotarget.12365↗
  21. The activation of c-Jun NH₂-terminal kinase is required for dihydroartemisinin-induced autophagy in pancreatic cancer cells. First author DOI 10.1186/1756-9966-33-8↗
  22. Dihydroartemisinin enhances Apo2L/TRAIL-mediated apoptosis in pancreatic cancer cells via ROS-mediated up-regulation of death receptor 5. Co-author DOI 10.1371/journal.pone.0037222↗
  23. [Experimental study of the function of nuclear factor-κB-dependent epithelial to mesenchymal transition in pancreatic cancer cells under hypoxic conditions]. Co-author PMID 22883954↗
  24. Dihydroartemisinin inhibits angiogenesis in pancreatic cancer by targeting the NF-κB pathway. Co-author DOI 10.1007/s00280-011-1643-7↗
  25. Nuclear factor-κB-dependent epithelial to mesenchymal transition induced by HIF-1α activation in pancreatic cancer cells under hypoxic conditions. Co-author DOI 10.1371/journal.pone.0023752↗

Closest collaborators

The 25 strongest of 53 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yongwei Wang · 15 shared papers, 2011–2026 · strength 1.28
  2. Jisheng Hu · 9 shared papers, 2017–2026 · strength 1.21
  3. Bei Sun · 16 shared papers, 2011–2023 · strength 1.13
  4. Guanqun Li · 5 shared papers, 2018–2026 · strength 0.82
  5. Shangha Pan · 12 shared papers, 2011–2023 · strength 0.81
  6. Yan Luo · 4 shared papers, 2023–2026 · strength 0.75
  7. Le Li · 5 shared papers, 2017–2026 · strength 0.71
  8. Le Li · 7 shared papers, 2016–2023 · strength 0.67
  9. Yilong Li · 8 shared papers, 2016–2022 · strength 0.67
  10. Hongze Chen · 6 shared papers, 2016–2023 · strength 0.63
  11. Bei Sun · 4 shared papers, 2019–2026 · strength 0.60
  12. Le Li · 4 shared papers, 2016–2026 · strength 0.60
  13. Gang Wang · 5 shared papers, 2016–2026 · strength 0.58
  14. Zhongjie Zhao · 5 shared papers, 2016–2023 · strength 0.56
  15. Xuewei Bai · 6 shared papers, 2011–2026 · strength 0.48
  16. Wenbo Yang · 3 shared papers, 2023 · strength 0.45
  17. Danxi Liu · 3 shared papers, 2022–2023 · strength 0.42
  18. Bei Sun · 2 shared papers, 2023–2026 · strength 0.42
  19. Qiushi Lin · 3 shared papers, 2019–2026 · strength 0.38
  20. Lianxin Liu · 3 shared papers, 2019–2026 · strength 0.38
  21. Katsuya Nagaoka · 3 shared papers, 2019–2026 · strength 0.38
  22. Xiaoqun Dong · 3 shared papers, 2019–2026 · strength 0.38
  23. Jack R. Wands · 3 shared papers, 2019–2026 · strength 0.38
  24. Kosuke Ogawa · 3 shared papers, 2019–2026 · strength 0.38
  25. Howard P. Safran · 3 shared papers, 2019–2026 · strength 0.38

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.